1. Home
  2. HG vs SUPN Comparison

HG vs SUPN Comparison

Compare HG & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HG
  • SUPN
  • Stock Information
  • Founded
  • HG 2013
  • SUPN 2005
  • Country
  • HG Bermuda
  • SUPN United States
  • Employees
  • HG N/A
  • SUPN N/A
  • Industry
  • HG
  • SUPN Biotechnology: Pharmaceutical Preparations
  • Sector
  • HG
  • SUPN Health Care
  • Exchange
  • HG Nasdaq
  • SUPN Nasdaq
  • Market Cap
  • HG 1.9B
  • SUPN 2.0B
  • IPO Year
  • HG 2023
  • SUPN 2012
  • Fundamental
  • Price
  • HG $19.06
  • SUPN $37.03
  • Analyst Decision
  • HG Buy
  • SUPN Hold
  • Analyst Count
  • HG 8
  • SUPN 1
  • Target Price
  • HG $21.50
  • SUPN $36.00
  • AVG Volume (30 Days)
  • HG 416.4K
  • SUPN 380.3K
  • Earning Date
  • HG 11-06-2024
  • SUPN 11-04-2024
  • Dividend Yield
  • HG N/A
  • SUPN N/A
  • EPS Growth
  • HG 537.51
  • SUPN 130.79
  • EPS
  • HG 4.48
  • SUPN 1.07
  • Revenue
  • HG $2,266,708,000.00
  • SUPN $651,972,000.00
  • Revenue This Year
  • HG N/A
  • SUPN $7.82
  • Revenue Next Year
  • HG $7.19
  • SUPN N/A
  • P/E Ratio
  • HG $4.25
  • SUPN $34.25
  • Revenue Growth
  • HG 68.94
  • SUPN 6.79
  • 52 Week Low
  • HG $12.44
  • SUPN $25.53
  • 52 Week High
  • HG $20.71
  • SUPN $39.37
  • Technical
  • Relative Strength Index (RSI)
  • HG 59.89
  • SUPN 59.47
  • Support Level
  • HG $18.83
  • SUPN $35.85
  • Resistance Level
  • HG $19.29
  • SUPN $37.41
  • Average True Range (ATR)
  • HG 0.38
  • SUPN 1.15
  • MACD
  • HG 0.08
  • SUPN -0.01
  • Stochastic Oscillator
  • HG 78.92
  • SUPN 62.72

About HG Hamilton Insurance Group Ltd. Class B

Hamilton Insurance Group Ltd is a specialty insurance and reinsurance company. It operates globally, with underwriting operations in Lloyd's, Ireland, Bermuda, and the United States. It operates three principal underwriting platforms (Hamilton Global Specialty, Hamilton Select and Hamilton Re) that are categorized into two reporting business segments: International and Bermuda.

About SUPN Supernus Pharmaceuticals Inc.

Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. The Company's diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.

Share on Social Networks: